Trials / Completed
CompletedNCT03830281
A Study Comparing LY900014 to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes Using Insulin Pump Therapy
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog in Adults With Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 471 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The reason for this study is to compare the study drug LY900014 to insulin lispro (Humalog) when both are used in insulin pump therapy in adults with type 1 diabetes (T1D).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ultra-Rapid Lispro | Administered SC |
| DRUG | Insulin Lispro | Administered SC |
Timeline
- Start date
- 2019-02-14
- Primary completion
- 2020-01-06
- Completion
- 2020-01-06
- First posted
- 2019-02-05
- Last updated
- 2021-01-22
- Results posted
- 2021-01-22
Locations
83 sites across 11 countries: United States, Australia, Austria, Canada, France, Germany, Hungary, Israel, Italy, Puerto Rico, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03830281. Inclusion in this directory is not an endorsement.